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Title:  To Compare The  Anti-Inflammatory Effect Of Oral hypoglycemic Drugs
In Type 2 Diabetes Mellitus
Aim: To compare the anti-inflammatory effects of Metformin sulfonylurea and
Sitagliptin combination with Metformin Sulfonylurea and Acarbose combination
in Type2DM patients by using Anti-inflammatory markers (IL6, hs CRP) and also
To compare the clinical outcome between these two groups by using the following
parameters FBS, PPBs, HbA1C, Plasma Insulin.
Materials and Method : In this study 30 type 2 diabetes patients on Metformin
and Sulfonylurea combination ,HbA1c value >7.5 were recruited and randomized
into two groups in which one group was added on Acarbose and the other group
was added with Sitagliptin along with Metformin, Sulfonylurea combinations and
followed for 3 months.
Result :
In this study Sitagliptin combination  reduced the mean value of FBS, PPBS,
HbA1c, Plasma Insulin , Insulin Resistance ,hsCRP and IL-6 , which were similar
to the results of previous studies. In Acarbose combination, there was a reduction
in the mean values of FBS,PPBS, HbA1c, Plasma Insulin, Insulin Resistance,
hsCRP but not IL-6. Hence long term follow up and large sample size may be
required to see the progression in the reduction of inflammatory markers and the
role of these drugs in the insulin resistant states.
Conclusion : This study explained the synergism when Sitagliptin given along
with Metformin Sulfonylurea combination and has proved  a definite role in
reducing chronic inflammation.
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INTRODUCTION: 
 Diabetes mellitus is one of the non communicable disease which 
has become a major global health problem. India is one of the topmost 
countries which has high prevalence of  diabetes 1 ,and this  is mainly due 
to insulin resistance or  decreased production of insulin, and thereby 
reflecting the increased glucose level in blood. This is again the main 
cause for increasing in the  incidence of type 2 Diabetes Mellitus2.Insulin 
resistance, one of the key feature common to obesity and type 2 DM, is 
associated with Endothelial dysfunction  and contributes to increased 
cardiovascular risk3. Hence Insulin resistance and endothelial dysfunction 
shares multiple signaling pathways which include hyperinsulinemia, 
gluco & lipotoxicity and inflammation 3. 
 Therapeutic intervention is needed in this phase apart from regular 
diet and exercise, to prevent micro and macrovascular complications. 
Metformin is the very commonly used oral hypoglycemic agent to control 
type 2 DM and approved as the first line drug for Type 2 diabetes. The 
newer agents such as (DPP-4 inhibitor) Sitagliptin, Vildagliptin, 
Saxagliptin, Linagliptin have been recently recommended by ADA in the 
therapeutic intervention of Diabetes Mellitus.  
 Gliptins are very effective in raising the insulin level by increasing 
the availability of Incretin and decrease the level of glucagon and thereby 
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reduce the plasma glucose concentration2.Hence used as an additive 
therapy in type 2 DM. Recently studies show that Gliptins have been 
proved to exert an anti-inflammatory action4. Acarbose, α-glucosidase 
inhibitor helps in reducing the postprandial hyperglycemia and has its 
effects towards the reduction of inflammatory markers. Metformin also 
has anti inflammatory action apart from its action in reducing the blood 
glucose level. Hence, the study objective is to compare the anti-
inflammatory effects of these oral hypoglycemic agents in Diabetes 
Mellitus. 
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OBJECTIVES OF THE STUDY 
 PRIMARY OBJECTIVE: 
To compare the anti-inflammatory effects of Metformin sulfonylurea and 
Sitagliptin combination with Metformin Sulfonylurea and Acarbose 
combination  in Type2DM patients by using Anti-inflammatory markers 
(IL6, hs CRP) 
SECONDARY  OBJECTIVE : 
To compare the clinical outcome between these two groups by using the 
following parameters 
• FBS, PPBS 
• HbA1C 
• Plasma Insulin 
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REVIEW OF LITERATURE 
 Prevalence of type II DM is increasing worldwide. By 2010, it was 
found that 285 million people around world have diabetes, of which 80% 
are from developed countries areas. Among those aged 20-79 years 6.6% 
have diabetes globally. The region with highest prevalence rate, at 11.7%, 
is North America and the Caribbean. The largest increase will be in 
countries like India and China where there is practice of increase 
consumption of high energy food, increasing adoption of sedentary 
lifestyle and urbanization. The prevalence of diabetes is expected to reach 
about 438 million by 2030, an increase of 54% compared to predicted 
figures of 20105. 
 Currently India has more number of people with diabetes mellitus. 
With a prevalence of 40.9 million in 2007, which may rise to 69.9 million 
by 20256. 
 A Survey was carried out in six cities in 2001on age –standardized 
prevalence rate, of which there was incidence of 12% for diabetes and 
14% for IGT. Patients under 40 years had prevalence of 5% and 13%of 
diabetes and IGT respectively7. 
 A recent study conducted by Chennai Urban Rural Epidemiology 
Study (CURES-17) reported that prevalence of diabetes was found to be 
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14.3%8. Another secular trend is the shift towards younger onset of 
diabetes, especially in urban areas, where up to 36% of those with 
diabetes are aged 44 years or less 8,9. 
 The Chennai Population Study (CUPS) has revealed the incidence 
of diabetes to be 20.2 cases per 1000 person-year and that of pre-diabetes 
was found to be 13.1 per 1000 person –year 10. 
 Identification of high risk and awareness should be increased 
among the public, because lifestyle modification has been shown to be 
effective in reducing progression from IGT to diabetes in Indian 
population 11. 
Type 1 Diabetes (β-cell destruction) 
• Most commonly Autoimmune 
• Rarely Idiopathic 
Type 2 Diabetes   (insulin hypo secretion with insulin resistance) 
Other types 
• Various endocrinopathies 
• Drug induced 
• Chemical induced 
• Infections 
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 There are many risk factors associated with increased incidence of 
T2DM. These include age, dietary excess, sedentary lifestyle dietary 
factors such as increase intake of animal fats, carbonated drinks, history 
of gestational diabetes, PCOS, several mental illness, hyperlipidemia, 
Obesity Positive family history, presence of Hypertension. The cluster of 
some of these factors like high blood pressure, increased blood glucose, 
high triglyceride, decreased HDL and obesity is termed as Metabolic 
Syndrome. These risk factors are also due to westernization and 
urbanization 12. 
                Figure.1:Influence of risk factors on Diabetes 
 
 Obesity has 80-85% risk of developing T2DM 13. Central adiposity 
is linked with insulin resistance and improper function of β cell, through 
high level of free fatty acids also linked with dyslipidemia and high BP. 
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Metabolic syndrome has risk as high as 2-5 folds for developing Type 2 
DM 14. 
 Recent studies have shown that sleep duration of about 5hrs or less 
leads to 47% increase in the incidence of diabetes over a period of 10 
years 15.Underlying mechanism between decreased sleep and onset of 
diabetes is not clear, but still it may be related to activation of the 
sympathetic nervous system, decrease cerebral glucose utilization, 
changes in hypothalamic –pituitary-adrenal axis as well as other 
neuroendocrine deregulation 15. 
 Some commonly used medications may cause various  metabolic 
changes and high risk of diabetes 16. Usage of high dose Thiazide 
diuretics are known to aggravate insulin resistance and β blockers can 
affect the insulin secretion. Atypical antipsychotics, have found to cause 
hyperglycemia and diabetes17. Increasing use of highly effective 
antiretroviral therapy (HAART)has reduced the mortality of  HIV 
patients however it also causes impaired glucose levels, resistance to 
insulin and lipid metabolism with more risk for  Type 2  DM 18. 
 Environmental toxins like persistent chlorinated compounds and 
brominated flame retardants have association with diabetes. These 
substances get accumulated in adipose tissue and functions like endocrine 
disruptors, which causes improper regulation of lipid and glucose 
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metabolism 19, 20. Maternal undernutrition, low infant birth weight, along 
with rapid postnatal growth, is found to be linked with high risk of 
diabetes in the child. This mismatch is found to be programmed during 
intra-uterine development and the nutritionally rich postnatal 
environment. Offspring of women who are obese or with diabetes have an 
increased risk of diabetes 21, 22. Hence earlier life events like low birth 
weight and fetal malnutrition may also have its effects in causing diabetes 
and cardiovascular disease in later life 23. 
INSULIN SECRETION  
 Pancreatic islet is a vascularized, highly innervated organ that 
contain four endocrine cell types secreting different hormone 
• Alpha(α) cells – glucagon 
• Beta(β) cells – glucose 
• Delta(δ) cell - Somatostatin, and  
• Eeta(ε) cells that secrete ghrelin. 
  Insulin and glucagon are important pharmacological agents in the 
treatment of diabetes. 
 Insulin normally formed as single polypeptide known as 
preproinsulin,then processed to proinsulin and then to insulin and C-
peptide. These processes take place in golgi complex, endoplasmic 
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reticulum and importantly the distinctive secretory granules of the β cell. 
Insulin has a t1/2 of 5-6 minutes due to extensive hepatic clearance 24. 
 C-peptide in contrast with no known physiological function or 
receptor has a t1/2 of ~30 minutes. Because almost all of the C-peptide 
released into the portal vein reaches the peripheral circulation where it 
can be measured, this peptide is useful in assessment of β-cell secretion, 
and to differentiate endogenous and exogenous hyperinsulinemia. 
REGULATION OF INSULIN SECRETION  
 The main secretagogue of insulin is glucose, and secretion of 
insulin is tightly associated to the extracellular glucose concentration. 
Insulin secretion is much greater when the similar amount of glucose is 
delivered orally compared to intravenously (incretin effect). Islets are 
mainly supplied by   adrenergic, cholinergic nervous system.  
• α2 adrenergic stimulation - inhibits secretion of insulin  
• β2 adrenergic receptor agonists,vagal nerve stimulation - enhance 
release.  
• Glucagon and somatostatin  -  inhibit insulin secretion. 
Conditions such as hypoglycemia,  hypoxia, exercise, surgery, 
hypothermia, and severe burns decreases the insulin secretion by 
stimulation of α2 receptors. Hence, α2 adrenergic antagonists increase 
 basal insulin concentration
concentration 24. 
Figure .2: Insulin secretion 
 During resting state of pancreatic cell 
entering via GLUT transporters (primarily
rodents), is metabolized
glucose stimulated insulin secretion.Glucose
glycoltic pathway produces NADP
inhibits K+ entry by
depolarization, which leads
secretory granules. The K
, and β2 antagonists decrease
 
it is hyperpolarized
 GLUT1 in humans, GLUT2 in 
(phosphorylated by glucokinase) increases 
-6-phosphate
 and elevates cellular ATP,
 KATP channel, reduced K
+ conductance 
 to Ca2+-dependent exocytosis of
ATP channel, composed of SUR1 and Kir 6.2 
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subunits, is the point of action of several group of drugs: ATP binds and 
inhibits Kir 6.2 whereas meglitinides, sulfonylureas binds as well as 
inhibits SUR1; all these three agents thereby promote insulin secretion.  
 These intracellular events are regulated by a number of processes, 
such as alteration in cAMP production, metabolism of amino acid and 
transcription factor levels. GPCRs for Gastro Intestinal Peptide, 
Glucagon, and Glucagon like Peptide-1 attaches to Gs stimulating 
adenylylcyclase and insulin secretion; receptors for somatostatin and α2 
adrenergic agonists couple to Gi to reduce cellular cAMP production and 
secretion. Incretins enhance insulin secretion. Diazoxide and ADP-Mg2+ 
(low ATP) binds as well as activates SUR1, thereby inhibiting secretion 
of insulin 24. 
INSULIN ACTION AND ITS SIGNALING PATHWAY 
 Insulin binds to the receptor that activates downstream signaling. 
Insulin binding stimulates tyrosine kinase activity of dimer, results in 
tyrosine phosphorylation and specific substrates like the Insulin Receptor 
Substrate (IRS) proteins, Gab-1 and SHC; within the membrane, a 
caveolar pool of insulin receptor phosphorylates caveolin (Cav), Adaptor 
protein having PH and  SH2 domains( APS), and Cbl -protein. 
                     Figure .
 These tyrosine
SH2 and SH3 and
(Gab-1) and SHC, 
and activates mitogen
there by it produces cell growth,differentiation and 
 In target tissues such as skeletal muscle and adipocytes, a key event 
is the translocation of the GLUT
This translocation is stimulated by both the caveolar and non
pathways. In the non
and PKB/Akt (anchored at the membrane by PIP3) an
3: Insulin signaling pathway and its action.
-P proteins react with signaling cascade
 mediate effects of insulin.Grb-2 associated binder 
within the membrane activates the following signals 
-activated protein kinase ( MAP k
survival
4 from vesicles to the plasma membrane. 
-caveolar pathway, the activation of PI3K is crucial, 
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inase) pathway 
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d/or an atypical 
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form of PKC is involved. IRS proteins are also involved in protein 
synthesis and glycogen synthesis24. 
  In the caveolar pathway, caveolar protein flotillin localizes the 
signaling complex to the caveola; the signaling pathway involves series 
of SH2 domain interactions that add the adaptor protein chicken tumor 
virus regulator of kinase II  (CrkII,) C3G, and GTP-binding protein, 
TC10. 
 GLUT4 is present in insulin-responsive tissues like skeletal 
muscle, adipose tissue that forms main sites of glucose disposal during 
meal ingestion. GLUT4 is one of a family of 13 glucose transporters in 
humans that shares 12 membrane-spanning domains. GLUT4 is 
noteworthy among these transporters as the most dependent on discrete 
stimuli by insulin or other effectors; normally GLUT4 resides in the 
intracellular space. Once the insulin receptors are stimulated, GLUT4 is 
shifted quickly to plasma membrane to facilitate inward transport of 
glucose. Insulin signaling also reduces GLUT4 endocytosis, increasing 
the residence time of the protein in the plasma membrane. 
 Following the facilitated diffusion into cells along a concentration 
gradient, glucose is phosphorylated to glucose-6-phosphate (G-6-P) by a 
family of hexokinases. Hexokinase II is found in relation with in adipose 
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tissue. Like GLUT4, hexokinase II is regulated transcriptionally by 
insulin. G-6-P is a branch-point substrate that can enter several pathways. 
G-6-P can be isomerized to G-1-P by phosphoglucomutase, and then the 
G-1-P can be stored as glycogen (insulin enhances the activity of 
glycogen synthase); G-6-P can enter the glycolytic pathway (leading to 
ATP production); G-6-P can also enter the pentose phosphate pathway 24. 
INSULIN ACTION 
 The insulin receptor is seen on all mammalian cells, explaining the 
wide range of responses to insulin. The tissues involved in regulation of 
blood glucose are liver, skeletal muscle, and fat .However, recent 
evidence suggests that specific regions of the brain and the pancreatic 
islet are also important targets for insulin. 
  Systemically, the insulin action is anabolic, and insulin signaling is 
important for uptake, use, and storage of glucose, amino acids and lipids. 
Importantly, it not only activates lipogenesis, glycogenesis and protein 
synthesis, but also inhibits catabolism. On a cellular level, insulin 
activates the transport of ions and substrates, promotes translocation, 
regulates the action of specific enzymes, and controls mRNA translation, 
gene transcription. 
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  Other action of insulin such as stimulating glucose and ion 
transport and phosphorylation or dephosphorylation of specific enzymes 
occurs within seconds or minutes. It takes over minutes to hours for 
actions, like promoting synthesis of protein and regulating transcription 
of gene. The actions of insulin on cell proliferation and differentiation 
occurs over days. Metabolic effects such as inhibition of lipolysis or 
hepatic glucose production occur rapidly, within minutes of increasing 
concentrations of plasma insulin; detectable increases in glucose 
clearance from the blood may take nearly an hour.  
 The variability in the kinetics of insulin action is probably due to 
variable access to insulin receptors in different tissues, distinct 
intracellular signaling pathways, and the inherent kinetics of the various 
processes controlled by insulin 
INSULIN RESISTANCE AND TYPE2DM: 
 Type 2 DM is characterized by improper secretion of insulin, 
resistance to insulin, increased glucose production in liver, and abnormal 
lipid metabolism. Obesity is very common in type 2 DM. 
  Abnormal insulin secretion, insulin resistances are important 
factors involved in development of type 2 DM. Most studies say that 
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insulin resistance occurs before the insulin secretory defect but type 2 
DM develops only when insulin secretion becomes less. 
 
 Earlier stages of diabetes, glucose tolerance found to be normal, 
because pancreatic beta cell produces a compensatory increase in insulin 
output which leads to insulin resistance after a certain period of time. 
Certain individuals can’t sustain hyperinsulinemic state produced by 
progressive increase in insulin resistance and compensatory 
hyperinsulinemia in the pancreatic islets cell . Later this leads to a state 
called Impaired Glucose Tolerance(IGT), where  there will be high 
postprandial glucose. 
 A reduction in secretion of Insulin and high hepatic glucose 
formation leading to overt diabetes with increasing blood glucose values, 
this indicates failure of beta cells. 
IMPAIRED INSULIN SECRETION 
 The β cell sensitivity to glucose is impaired in type2 DM; also 
there is reduced response to other stimuli such as insulinotropic GI 
hormones and neural signaling which ends in delayed production of 
insulin, which cause blood sugar to rise after meals, and failure to reduce 
the liver glucose release during fasting. Apart from the defect in 
functional properties of the cell, the absolute mass of cells is also reduced 
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in type 2 diabetes patients. The deficit is proceeded by a gradual loss of 
βcell mass over a period of time. This is futher related to toxic effects of 
hyperglycemia. Hence due to progressive reduction of βcell mass and 
function, patients with type2DM require steady increase in therapy to 
maintain glucose level. 
  Higher fasting glucose levels and insulin resistance shows a 
elevated levels of fasting Insulin. Increased amount of proinsulin is the 
other factor contributing to apparently high insulin levels early in the 
course of the disease. Proinsulin, the precursor to insulin, is inefficiently 
processed in the diabetic islet. Whereas healthy subjects have only 2-4% 
of total circulating insulin as proinsulin, type 2 diabetic patients can have 
10-20% of the measurable plasma insulin in this form. Proinsulin has a 
considerably attenuated effect for lowering blood glucose compared to 
insulin24. 
             Secretion of insulin and sensitivity are related to one another. In 
type 2 Diabetes mellitus, insulin secretion first increases in relation to 
insulin resistance to keep up normal glucose levels. In early stages, the 
insulin secretion deficit is mild. 
 Abnormalities in proinsulin processing are reflected by increased 
secretion of proinsulin in type 2 diabetes. Finally, the insulin secretion 
defect leads to less insulin secretion. 
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The reasons for reduction in insulin secretion in type 2 DM are unclear.   
• A secondary genetic defect with insulin resistance-causes beta cell 
dysfunction. 
• Amylin is found in the islets of individuals with long-standing type 
II Diabetes mellitus.  
• Glucose toxicity - the metabolic environment of diabetes like, long 
standing increased glucose levels impairs islet function leads to an 
increase in glucose levels. 
• Lipotoxicity- the increased levels of FFA and dietary lipid may 
also reduce islet function24. 
 
 Insulin resistance causes the impaired usage of glucose by sensitive 
tissues; it also elevates hepatic glucose output. Hence these are 
responsible to the increase blood sugar level. Elevated hepatic glucose 
output is the cause for increased Fasting Plasma Glucose levels; also 
reduced peripheral utilization of glucose ends PP hyperglycemia. 
 
Combined effect of genetic susceptibility and obesity causes the 
insulin resistance which leads to the reduced capacity of insulin to act 
prominently on target tissues a main feature of diabetes .Insulin resistance 
is low, because high levels of plasma insulin will alter the  blood glucose 
level to normal. Greater impairment in glycogen formation is seen in 
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skeletal muscle (non oxidative glucose utilization) whereas no alteration 
of glucose metabolism in insulin-independent tissues. 
 
 The main molecular mechanism underlying insulin resistance in 
diabetes does not have a clear explanation. Tyrosine kinase activity and 
insulin receptor levels in skeletal muscle are decreased, but still changes 
are mostly secondary to increase insulin secretion and not primary defect. 
Hence, defects in insulin-mediated phosphorylation/dephosphorylation 
appear to have a main role in resistance (PI-3-kinase signaling defect 
might reduce the membrane translocation of GLUT4). Other impairments 
like the accumulation of lipid in skeletal muscle cells might impair 
phosphorylation of mitochondrial oxidation and decrease insulin-
generated production of ATP in mitochondria. Additionally, these 
impairments may produce reactive oxygen species such as lipid 
peroxides. 
 
 Importantly, all insulin signaling pathways are not resistant, like 
those involving, cell growth control and differentiation through the MAP 
kinase (mitogenic-activated protein kinase) pathway. Hence as a result, 
hyperinsulinemia may enhance the insulin action through these pathways, 
which led to aggravation of diabetes-related conditions such as 
atherosclerosis. 
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 In diabetes hepatic insulin resistance suppresses gluconeogenesis 
which shows the failure of hyperinsulinemia. This results in elevation of 
fasting blood glucose and reduced hepatic glycogen storage during the 
postprandial state 2. 
 In the earlier period of diabetes, after the raise of impairment in 
insulin secretation and resistance of insulin in the skeletal muscle, 
increased hepatic glucose production is being established.In adipose 
tissue as a result of resistance, increased free fatty acid and lipolysis 
occurs from adipocytes, which in turn leads to increased 
triglycerides,VLDL levels and reduced HDL (high density lipoprotein) 
synthesis in hepatocytes leading to dyslipidemia which occurs  in type 2 
DM patients after a certain period of time. This lipid storage in the 
hepatic cells may cause nonalcoholic fatty liver disease 2. 
 
 The metabolic syndrome a insulin resistance state or syndrome X 
used to describe metabolic derangements that includes, hypertension, 
resistance of insulin, decreased HDL and increased triglycerides, type 2 
diabetes or IGT /IFG, central or visceral obesity, and increased 
cardiovascular risk with two types:  
 (1) Type  A, affects women of young age and is described by severe 
obesity, features of hyperandrogenism, and hyperinsulinemia.  
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 (2) Type B, affects middle-aged women, has severe features of 
hyperandrogenism, hyperinsulinemia, and autoimmune diseases. 
  
 Persons with type A insulin resistance syndrome have an undefined 
defect in the pathway of insulin-signaling; type B persons with resistance 
of Insulin syndrome show auto antibodies towards the receptor of insulin. 
The actions of these auto antibodies may prevent insulin binding or 
activate insulin receptor, leading to intermittent low blood glucose level. 
Polycystic ovary syndrome (PCOS) is a common disorder, defined by 
hyperandrogenism and chronic anovulation. Resistance of insulin is seen 
in PCOS women, and thus increases the risk for type 2 DM, irrespective 
of the actions of obesity 2. 
 
INFLAMMATION AND INSULIN RESISTANCE 
 
  Obesity has low grade inflammation of white adipose tissue 
(WAT) which results due to chronic activation of innate immune system 
finally leading to resistance of insulin, impaired glucose tolerance and 
diabetes. 
The obesity in diabetes, with central or visceral fat plays a major 
role in the pathogenesis of DM. This leads to increased levels of fat cell 
products like, nonesterified free fatty acids, retinol-binding protein 4, 
leptin, TNF-α, resistin, adiponectin and free fatty acids in circulation. 
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Adipokines not only regulates, appetite, body weight and energy 
expenditure, it additionally modulate the sensitivity of insulin. 
Adipokines and increase in free fatty acids production cause resistance of 
insulin in hepatic and skeletal muscle. For example, FFA affects usage of 
glucose in skeletal muscle increase synthesis of glucose in liver, and 
causes dysfunction of the beta cell. In contrast adiponectin,an insulin 
sensitizing peptide produced in the adipocytes  is decreased  in obesity 
and this may lead to resistance of Insulin activity in the  liver.  Products 
of adipocyte causes, a state of inflammation and explains why 
inflammatory markers like C-reactive protein and IL-6 are often 
increased in type 2 DM . In addition, inflammatory cells have been found 
infiltrating adipose tissue 2. 
 
TNF-α 
 
 It is a proinflammtory cytokine produced from macrophages and 
lymphocytes. It is also synthesized  weakly by adipose tissue in 
humans.TNF-α may have important part  in pathophysiology of insulin 
resistance mediated by the serine  phosphorylation of the insulin receptor 
substrate (IRS-1) instead of phosphorylation of tyrosine and thereby 
stopping the pathway of  insulin signaling. Moreover adipose tissue is not 
related in increasing levels of TNF-α in circulation, it can be 
hypothesized that other mechanism like leptin derived from adipose 
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tissue may produce TNF-α from macrophages. Hence further 
investigations are required in searching the of TNF-α activities in obese 
people 25. 
Interleukin-6 
 Interleukin -6 is synthesized from cells like fibroblast, monocytes, 
endothelial cells and including adipose tissue. Adipose tissue which 
synthesis  IL-6 is increased in obese people. Secretion of IL-6 is high in 
visceral adipose tissue. It is a multiactional cytokine which is delt in the 
production of hepatic C-reactive protein, one of the independent factor 
for cardiovascular risk and its complications. Hence there is association 
between protein of IL-6 in adipose tissue and levels of IL-6 and CRP in 
circulation 26. 
 This shows that IL-6 has importance in inflammation, obesity, and 
cardiac disease 27. Increased visceral adipose tissue production of IL-6 
explains the association between deposit of central fat and complications 
of cardio vascular diseases. Since VAT is linked to liver by portal vein, 
IL-6 produced by adipose tissue increases the VLDL secretion and 
hypertriglyceridaemia affecting the liver metabolism 28. 
 Studies show that IL-6 could have been included in insulin 
resistance and its complications29. The interleukin 6 acts via JAK/STAT 
pathway which regulates target gene transcription 30.Hence through this 
pathway there is interaction between cytokine and insulin signaling 
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pathway thereby impairing the effects of insulin. Although the exact 
mechanisms is not known , it could be due to an interaction between 
suppressor of cytokine signaling (SOCS)proteins and the insulin receptor 
32,33 or tyrosine phosphatase activation 31. 
 
CRP 
 
 CRP is an acute-phase reactant synthesized in the hepatic cells   
due to activation of IL-6 and TNF-α derived from adiposity. It shows 
several fundamental immunoregulatory functions, specifically, CRP 
shows PRRs activation. CRP also plays role in modulation of platelet 
activity, complement fixation, increasing leukocyte reactivity, and 
clearance of cellular debris from active inflammatory sites 34, 35. 
 
 INFLAMMATION - INSULIN RESISTANCE - T2DM 
 It was hypothesized that conditions like inflammation could have a 
major role in the diabetes pathophysiology36. It has also been explained 
that along with pro-inflammatory effects of cytokines, other factors like 
free fatty acids and  reactive oxygen species in obesity acts by 
intracellular signaling pathways, which includes  the IκB kinase, (IKK), 
nuclear factor (NF)-κB, c-Jun NH2-terminal kinase(JNK) and Activating 
Protein-1 (AP-1) signaling molecules. They acts with insulin signaling 
through threonine /serine  inhibitory phosphorylation of IRS. 
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 Hence the IL-6  and TNF-α decreases the actions of insulin 
33,37,38,39. Thus along with increased risk of cardiovascular diseases 
mediated through inflammation, the gradual rise of cytokines in the 
circulation may add to the effects of resistance in insulin activity and 
hyperglycemic state.  
As duration and degree of hyperglycemia increases, the risk of chronic 
complication also increases like: 
Microvasular effect:  
• Retinopathy (nonproliferative/proliferative)  
• Macular edema  
• Eye disease 
• Sensory and motor (mono- and polyneuropathy) 
• Autonomic conditions  
• Neuropathy 
• Nephropathy 
Macrovascular effect: 
• Cerebrovascular disease 
• Coronary heart disease 
• Peripheral arterial disease 
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Others changes:  
• Gastrointestinal (gastroparesis, diarrhea) 
• Genitourinary (uropathy/sexual dysfunction) 
• Dermatologic 
• Infectious  
• Glaucoma 
• Cataracts 
• Hearing loss  
• Periodontal disease 
                     Diabetic individuals usually get these types of complications 
only after 20 years of onset of diabetes. But in case of type 2 ,  with  long 
period of asymptomatic phase of  hyperglycemia,  many people present 
with complications at the time of diagnosis 2. 
 
DIABETES - INFLAMMATION - CARDIOVASCULAR RISK 
 The hypothesis proposes that hyperglycemia and insulin resistance 
which lead to increase in free fatty acid production, forms diacylglycerol 
leading to stimulation of protein kinase C (PKC).Additionally,PKC 
modifies the gene transcription of fibronectin,  contractile proteins, type 
IV collagen and extracellular matrix proteins in neurons and  endothelial 
cells. Drugs  inhibiting   PKC  actions are being studied in clinical trials. 
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 Endothelial dysfunction is a main feature of type 2 diabetes 
mellitus (DM). Endothelial dysfunction is also present in patients with 
insulin resistant stages prior to the development of overt hyperglycemia 
(IGT) and type 2 DM. Many articles quotes that endothelial dysfunction 
has been described in women with gestational diabetes, obesity and 
individuals with the metabolic syndrome. This suggest that insulin 
resistance is main key factor  and endothelial dysfunction is not simply a 
result of hyperglycaemia. Early changes in the alteration of glycemic 
levels caused by impaired insulin secretion or obesity-related insulin 
resistance is the cause for structural and functional changes of the blood 
vessel leading to vascular complications of type 2 DM. 
 In diabetes and obese patients, there is rise in free fatty acid 
production which stimulates toll like receptor and continues the 
translocation of NF-kB and subsequently promotes the genes of 
inflammation like TNF-alpha and IL-6. Simultaneously JNK /protein 
kinase C decreases insulin receptor substrate-1 (IRS-1) phosphorylation 
and downstream Akt and PI3-kinase. Which further down-regulates the 
glucose transporter 4 and finally leads to resistance of Insulin. Impaired 
Insulin sensitivity in endothelium of the blood vessels promotes ROS 
formation, FFA oxidation, which subsequently stimulating the pathways 
like, PKC activation, AGE synthesis, and down-regulates PGI2. Finally 
eNOS activity is impaired leading to dysfunction of endothelium. In the 
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platelets impaired IRS1/PI3K pathway leads to accumulation of calcium 
and increases the aggregation of platelets 42, 43, 44. 
 
        Hyperglycemia which alters the vascular endothelium is due to the 
impaired balance between accumulation of reactive oxygen species 
(ROS) and nitric oxide causing dysfunction of endothelium 43. Increase in 
intracellular glucose levels leads to activation of PKC and production of 
ROS by the help pf NADPH oxidase and p66Shcadaptor protein. 
 Increase in oxidative stress gradually impairs NO activity and 
reduces the protein nitrosylation. Protein nitrosylation usually decreases 
the effect of endothelial NO synthase and antioxidant enzymes 44. PKC-
dependent eNOS deregulation also reduces the NO availability; this 
reduced bioavail-ability of NO is a prominent indicator of cardiovascular 
outcomes 44. 
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 Figure.4: Insulin resistance as a trigger of Artherothrombosis. 
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 PKC causes enzyme up-regulation thus increases, uncoupling of 
endothelial nitric oxide syntheses (eNOS) and further leading to 
accumulation of free radicals. Simultaneously, insulin resistance and 
hyperglycemia decreases eNOS activity. Along with the lack of NO, 
glucose-induced activation of protein kinase C (PKC) produces increased 
production of endothelin-1(ET-1) causing constriction of blood vessel 
and platelet aggregation. Collection of superoxide anion also causes 
enhancement of pro-inflammatory genes monocyte chemoattractant 
protein (MCP-1), intracellular cell adhesion molecule (ICAM-1) and 
vascular cell adhesion molecule-1(VCAM-1) by the signaling of NFkB . 
The sequential process progresses to monocyte adhesion, rolling and 
diapedesis along with foam cells formation in the layer of sub-
endothelium. Foam cell further increases cytokines of inflammation and 
keeps the proliferation of smooth muscle cells and vascular inflammation, 
thereby increasing the process of atherosclerosis. Furthermore, ROS 
enhances the production of glucose metabolite methylglyoxal leading to 
activation of AGE/RAGEsignalling and the pro-oxidanthexosamine and 
polyolpathway flux. Therefore there may be a common mechanism 
underlying both the development of endothelial dysfunction and insulin 
resistance 45- 51. 
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Figure .5: Insulin resistance and Endothelin  Dysfunction. 
 
CURRENT PHARMACOTHERAPY OF TYPE 2 DIABETES 
MELLITUS 
Adequate glycemic control is necessary to address acute symptoms 
and to prevent, defer or reduce the severity of chronic microvascular and 
macrovascular complications. Choice of drug should address the 
pathophysiology, and combinations of differently acting agents are 
frequently required to provide additive efficacy. So, the current oral 
hypoglycemic agents available for the therapeutic uses are  
  The Biguanide Metformin often selected as initial oral ant diabetic 
drug therapy. It counters insulin resistance and lowers blood glucose 
through several insulin dependent and independent mechanisms. 
Sulfonylurea act on the pancreatic β cells to stimulate insulin secretion. 
The efficacy of Sulfonylurea depends on adequate remaining function of 
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the beta cells. Meglitinides ,also called as prandial insulin releasers, are 
rapid short acting insulin secretagogue taken before meals to boost insulin 
levels during digestion, thereby reducing prandial hyperglycemia and 
decreasing risk of interprandial hypoglycemia. Thiazolidinediones 
produce slow onset glucose lowering effect, attributed mainly to 
increased insulin sensitivity (especially increases peripheral glucose 
utilization) by activating nuclear receptor PPAR-γ .Gliptins increases 
prandial insulin secretion by inhibiting DPP-4 enzymes, which in turn 
increases plasma half life of insulinotropic incretin hormones. The newer 
agents such as (DPP-4 inhibitor) Sitagliptin, Vildagliptin, Saxagliptin, 
Linagliptin have been recently recommended by ADA in the therapeutic 
intervention of Diabetes Mellitus. α-glucosidase inhibitors slows the rate 
of carbohydrate digestion by competitively inhibiting the intestinal α- 
glucosidase enzymes. 
Metformin 
Belong s to the class of Biguanide. It is the most largely prescribed 
insulin sensitizer in the management of type 2 diabetes. 
Primary effect of Metformin is to decrease liver glucose production 
by the stimulation of the AMP-activated protein kinase (AMPK) enzyme. 
It also have other mechanisms of action like impairing the production of 
gluconeogenesis in renal, decreasing in absorption of blood glucose from 
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the intestinal tract, direct stimulant for tissues glycolysis, and reduction in 
levels of plasma glucagon. 
 Action of Metformin does not depend on pancreatic beta cells 
function.  These agents are commonly called as euglycemic agents. 
Because biguanide therapy does not cause hypoglycemia in type 2 
diabetes patients.  
Metformin as pleotropic actions  on several tissues. Insulin resistance and 
hyperinsulinemia have their effects on adipose tissue, liver, endothelium 
skeletal muscles and ovary. Biguanide was shown to modulate 5’-AMP-
activated protein kinase (AMPK) dependent regulation, which in turn is 
upregulated by serine threonine protein kinase11 (SK 11). These signals 
are responsible for the suppression of genes encoding gluconeogenic and 
lipogenic liver enzymes (Acetyl coA carboxylase) there by inhibiting the 
hepatic gluconeogenesis and lipogenesis and increases the fatty acid 
oxidation 52, 53, 54.  
Figure .6 : Metformin action on Liver. 
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 Increase in basal insulin stimulates the glucose uptake and this 
process is done by Metformin in the skeletal muscle. The glucose uptake 
from skeletal muscle appears to be influenced by activation of AMPK 
followed by aPKC and GLUT-4 activation. The Insulin stimulated 
glucose uptake may involve the increase in the signaling of Insulin 
through the decrease in inflammation, lipotoxicity and glucotoxicity. By 
AMPK activation, biguanide also inhibit lipid production while 
increasing the skeletal muscle fatty acid oxidation. Thus result of the 
above actions may bedue to decrease in the resistance of insulin which in 
turn attenuates the postprandial blood sugar levels 55, 56. 
 
Figure.7: Metformin action on Skeletal Muscle. 
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 Metformin may act through the inhibition of Extracellular-signal-
regulated kinases (ERK1/2) phosphorylation which attenuates the TNF-α 
induced lipolysis in adipocytes; it also opposes expansion of adipose 
tissue by AMPK-dependent activation of oxidation of free fatty acid and 
attenuating the lipid production. This effect may contribute to decreased 
fat mass and antilipolytic action of metformin influence the sensitization 
of insulin by reducing the systemic FFA levels 57-62 .The Metformin’s 
action decreases the glucotoxicity and lipotoxicity and may improve 
sensitivity of insulin in adipose tissue. In visceral adipose tissue glucose 
uptake is done through AMPK-dependent mechanism .Metformin may 
also have its influence on adipokine secretion through mitogen activated 
protein kinase or AMPK 63 – 69. 
Figure.8: Metformin action on Adipose tissue. 
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METFORMIN ACTION ON ENDOTHELIUM 
  Metformin’s effect on the endothelium of blood vessel is based on 
the decrease in glucotoxicity and decrease in levels of advanced glycated 
end products as well as decrease in hyperinsulinemia/insulin resistance70. 
At the molecular level, these mechanisms combine to prove a balance by 
decreasing the MAPK and increase in the PI3K-dependent cascades. 
They have promising effects directly on blood vessel endothelium, by 
activation of AMPK, apart from blood sugar lowering and sensitization of 
insulin. As a result, treatment with metformin decreases NF-kB, thus 
decreases production of endothelin-1 (ET-1), proinflammatory cytokines 
(IL-6, IL-8,IL-18,TNF-α), Plasminogen activator inhibitor ( PAI-1), and 
adhesion molecules, while it increases eNOS and endothelial NO 
production 71. Through these mechanisms Metformin can prevents the 
endothelial dysfunction and decrease in atherosclerotic injury. Due to its 
spectrum of metabolic actions, metformin is a useful adjuvant to 
modification of lifestyle in obese and overweight PCOS patients who has 
IGT or metabolic syndrome features. 
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Figure.9: Metformin action on Endothelium 
 
In women with T2D and PCOS Metformin is the first-line choice 
of treatment. Metformin’s targets have been explored to add the ovary 
and the endothelium. Molecular studies have proven the mechanisms of 
Metformin actions via AMPK, a serine–threonine kinase which includes 
its action on the muscle, liver, endothelium, and the ovary. The direct 
endothelial actions biguanide appears to be useful in endothelial 
dysfunction 72. 
 
DPP-4 Inhibitor  
Sitagliptin, is a DPP-4 inhibitor, blocks the dipeptidyl peptidase enzyme 
that causes degradation of incretin which are produced with response to a 
meal, in turn increases incretin level and the insulin secretion and reduce 
the glucagon level, and thus it helps in improving the fasting and 
 postprandial hyperglycemia .Hence inhibitors 
increasing the insulin secretion.
Figure.10: Mechanism of 
Sitagliptin increases
1 and insulin tropic polypeptide
anti-diabetic effect.
 Studies shows that since DPP
membranes and known to 
Sitagliptin was hypothesized to 
study 22 diabetic patients 
100 mg daily or placebo for 12 
of DPP4
 
action of DDP-4 Inhibitors
 the bioavailability of incretin, glucagon
 dependent on glucose which implies 
 
-IV is present as CD26 on cell 
cause pro-inflammatory signals,
exert an anti-inflammatory
were randomized and given either
week period. Baseline investigations 
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Fasting blood samples were obtained before the starting of treatment and 
12 wk of treatment. Results showed that HbA1C, mRNA expression in 
mononuclear cell of CD26, proinflammatory cytokine,TNF alpha, Toll 
like receptor (TLR)-4, fell significantly after 12 weeks of Sitagliptin 
therapy. Plasma concentration of C-reactive protein, IL-6 and free fatty 
acid levels fell significantly after 12 weeks of Sitagliptin therapy. It 
concludes that these effects show a promising action of anti-inflammatory 
effect and thus helps in inhibition of atherosclerosis 73. 
 
 The anti-inflammatory actions of Sitagliptin may influence to a 
potential antiatherogenic action of Sitagliptin. Regarding this concept, 
retrospective meta-analysis of Sitagliptin treatment based studies shown 
that there was a greater reduction of about 50% in cardiovascular events 
in the Sitagliptin group than the controls 74. 
 Reno protective effect of Sitagliptin was investigated in study 
using Cisplatin induced nephrotoxicity in mice. In that study 48 male 
balb-c mice were equally divided into 4 groups as, control, Sitagliptin 
group, Cisplatin group and Cisplatin plus Sitagliptin group. The mice 
were sacrificed after 72 h of Cisplatin injection the results showed that 
Sitagliptin significantly decrease the nephrotoxic effect of Cisplatin with 
increased activity of antioxidant enzymes, improved kidney function, 
renal histopathological scoring and decreased tissue level of TNF-α. It 
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can be concluded that Sitagliptin may have a protective role against 
Cisplatin induced acute nephrotoxicity via antioxidant and anti-
inflammatory pathway. Thus from the study we came to know that 
Sitagliptin may exert antioxidant and anti-inflammatory role which will 
also help in preventing the atherosclerotic process 75. 
 Studies hypothesized that Sitagliptin, a DPP4-inhibitor, may also 
have a role in improving functions of endothelium in DM patients with 
coronary artery disease (CAD). 
 In that study, 40 patients with CAD and uncontrolled DM, were 
grouped for 6 months therapy of either add-on with Sitagliptin treatment 
or aggressive conventional treatment. Reactive hyperemia peripheral 
arterial tonometry index (RHI), was assessed for endothelial function 
  The change in RHI percent, was more in the Sitagliptin group than 
in the control group .Significant decrease in the high-sensitivity C-
reactive protein level was seen in Sitagliptin treated group, but no such 
change was seen in the control group. It was concluded that Sitagliptin 
significantly improve endothelial function and inflammatory state in 
uncontrolled DM patients with coronary artery disease, apart from its 
blood glucose lowering effect. Hence it suggests that Sitagliptin has 
beneficial actions on the cardiovascular system in diabetes patients 76. 
Recent researches had proved that Sitagliptin and Exendin-4 apart from 
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activating the phosphorylation of AMPK, it also inhibit the activation of 
MAPK including p38 and ERK 77- 80. Stimulation of AMP-activated 
protein kinase(AMPK), in vascular cells found to possess anti-
atherosclerotic effects 81-83 by increasing  the Akt/endothelial NO 
synthase (eNOS)/NO signaling pathway,which futher causes  suppression 
of p38 activation of nuclear factor-κB and following suppression of 
downstream inflammatory responses 83. It also suppresses mitogen 
activated protein kinase (MAPK) which has beneficial effects in 
atherosclerosis through decreasing adhesion molecules and anti-
inflammatory effects, as well as increases the stability of the carotid  
plaques 83 . 
Acarbose  
 
 Acarbose a competitive blockers of glycosidase and it decrease 
postprandial increase in blood glucose by prolonging the time of  
absorption and  digestion of starch and disaccharides .Glucose and 
fructose are the only monosaccharide that can be delivered  from the 
intestinal lumen and into the bloodstream. In case of other substances like 
starches, oligosaccharides, and disaccharides that must be converted to 
monosaccharides before getting absorbed in the duodenum  
50 
 
 The two enzymes, α glycosidase and pancreatic amylase, get bind 
to the brush border of the intestinal cells and facilitate the digestion 
process. 
α- glycosidase inhibitors decrease gastro intestinal absorption of 
dextrin disaccharides and  starch . Inhibition of α- glycosidase delays the 
absorption of carbohydrates from GI tract and decreases the rate of rise of 
postprandial plasma glucose. These drugs also increase the release of the 
glucoregulatory hormone GLP-1 into the circulation, which may 
contribute to their glucose-lowering effects24. Impaired glucose tolerance, 
destroys the endothelium of the arterial blood vessel which starts as a 
sequence of pro-atherogenic process are associated with the sudden 
increase in postprandial blood glucose levels 84, 85. 
Mechanisms underlying Acarbose will provide the cardiovascular 
benefits by directly pointing towards the postprandial blood glucose level, 
which limits and reduces the smooth muscle of endothelial damage which 
again decreases  the risk of diabetic complications.  
Study of STOP-NIDDM showed in prediabetes that  Acarbose 
delays the process of intima media thickening (IMT) in individuals 
compared to placebo, therapeutic management with Acarbose decreases 
approximately 50% (P = 0.027) 86 yearly rise in carotid IMT.  
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 Hence, the end result from substudy of STOP-NIDDM is also 
confirmed in the results of another sequential study, in which therapeutic 
management with Acarbose revealed to preserve vasodilatation of the 
endothelium compared to treatment with placebo. 
 The primary end point of the meta-analysis of improvement in risk 
factor by the treatment with Acarbose (MeRIA), which showed the 
results of 7 trials done in type 2 Diabetes, was the time taken to produce a 
cardiovascular event. The results proved that Acarbose treatment causes 
promising benefits in cardiovascular disease and damage 87. Therapeutic 
management with Acarbose, decreases the cardiovascular risk by 35% 
overall and the risk of MI specifically by 64% 87. 
 Diabetic patients are at high risk for the other components like 
dyslipidemia and hypertension leading to metabolic syndrome, these 
components of metabolic syndrome has been cause for raise in morbidity 
and mortality 88, 89 .Hence  prevention of diabetes and cardiac disease will 
be the primary aim in the management of metabolic syndrome 90. Hence 
the studies have shown that Acarbose treatment has been shown to have 
promising results for metabolic syndrome. 
 The usage of  other oral antidiabetes agents like thiazolidinediones,  
sulphonylureas are associated with 2-5 kg weight gain 91 but a  another  
RCT done with acarbose and glibenclamide as monotherapy has found no 
change in weight in patients with Acarbose treatment 92 .After 3 years 
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treatment with Acarbose , individuals had shown reduction in the mean 
value of around 1.2kg, compared with controls. 
 Percentage of around 20% to 60% of diabetic patients will be at 
high risk to develop hypertension 93. Another study in fourty four type 2 
diabetes patients found reduction in systolic, diastolic and mean blood 
pressure values along with good glycaemic control in Acarbose 
treatment94. In the same way another randomized study in obese diabetes 
patients found that treatment with Acarbose showed decrease in blood 
pressure by 6 month treatment, compared to Glibenclamide 95. 
 Decrease  in postprandial hyperglycemia in diabetes patients after  
Acarbose treatment have also been shown to decrease the 
proinflammatory transcription factor (NFκ B) activity and nuclear 
localization 96 . This suggest a underlying mechanism of Acarbose in their  
anti-inflammatory effects .This would be associated with decrease  in 
coagulation factors levels after treatment with Acarbose. This was shown 
by acarbose which reduces the fibrinogen level in type 2 diabetic 
patients97, and decreases the serum CRP values in patients with IGT 98.  
Studies have shown that Acarbose improves the insulin sensitivity 
in elderly diabetic patients 99. Limiting factor of excess insulin is 
hypoglycemia 100,101 .This is the major reason for mortality and morbidity 
102 but due to its different mode of action; Acarbose doesn’t activate the 
secretion of Insulin and doesn’t cause hypoglycemia on monotherapy 101. 
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Systemic availability of Acarbose is less than 2 % and so the toxic 
reaction is probability is very low and no drug interactions.103, 104. 
In a study, 20 diabetes patients with liver disease Acarbose therapy 
reduces the HbA1c after 8 weeks of therapy 105 and reduces postprandial 
blood sugar levels by about 50% 106 . 
Diabetic related complications are more common in elderly 
patients. Study conducted in elderly diabetic patients found that treatment 
with Acarbose monotherapy showed reduced blood sugar levels, without 
causing hypoglycemia and there were no revelant clinical changes in vital 
signs within the period of treatment 107,108. 
It was demonstrated  that the safety of Acarbose in  long-term in 
post marketing survillence and in placebo controlled trials showed that 
combination of acarbose plus other antidiabetic therapies proved  a better 
safety profile 109 .  
The compliance of Acarbose therapy is affected by the adverse 
effects like mild gastro intestinal events, and effects may be reduced by 
low dosing regimen in the starting of the treatment. But still Acarbose has 
a better safety profile, and so it is good for the treatment of type 2  
diabetes and one of the very few oral hypoglycemic drugs approved by 
FDA for management of prediabetes.  
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Thus finally, the Acarbose has been shown to decrease the risk of 
cardiovascular events irrespective of patient’s weight and age. 
 
Sulphonylurea 
 
 
Role of Sulfonylurea’s is to rise insulin release from pancreas by 
two additional mechanisms of action- a decrease in  serum glucagon 
levels and potassium channel closer in extra pancreatic tissue.  
The sulfonylureas continue to be widely prescribed which are 
divided into first-generation and second-generation. They differ mainly in 
their potency and adverse effects. The first generation sulfonylurea are 
not used much now a days as the second-generation agents become 
generic and less cost . 
These potent sulfonylurea like Glipizide, Glyburide, and 
Glimepiride—should be used cautiously in cardiovascular disease 
patients or in patients of elderly age group, in whom hypoglycemia would 
be especially dangerous 
Studies done in animals proved that sulfonylurea shows their 
actions by getting attached to sulfonylurea receptors (SUR), which futher 
connected to ATPdependent k+channels.  Receptor SUR1 binding in 
pancreatic beta cells shows  insulinotropic effects 110-113.  
 Other sulfonylurea’s also binds and have effect on receptors 
SUR2A/B present over the coronary smooth muscle and myocardium 
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thereby preventing ischemic preconditioning which is said have a   
protective role 113 .Interference with ischemic preconditioning which is 
proven to have adaptive role (a phenomenon where repeated exposure to 
mild or moderate ischemia protects the myocardium against damage 
during subsequent episodes of severe ischemia.) may be the cause for 
these adverse cardiac effects of sulfonylurea 113. 
 The second generation sulfonylurea’s like Glipizide or  Gliclazide 
shows little binding or affinity over SUR2  and have shown a favorable  
outcomes in cardiovascular disorders, in their initial period of therapeutic 
management 114.  Studies which were done retrospectively have shown 
that Glimepride and Glibenclamide which have low affinity for SUR 1 
selectivity ,were  associated with more events in cardiovascular disorders 
like angina, myocardial infarction, peripheral vascular disease and 
stroke.114 . 
ANTI-INFLAMMATORY EFFECTS OF ORAL 
HYPOGLYCEMIC AGENTS AND THEIR PRESENT 
STATUS. 
 Previous study by Andrew et al, has shown that Obese diabetic 
patients treated with metformin had lower levels of hsCRP ,expression of 
TNF-α and TLR 2/4, than their counterparts receiving placebo 115 . The 
results from the previous studies  proved that Acarbose treatment causes 
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promising benefits in cardiovascular disease and damage 87 .Another 
study done with Acarbose has proven that it decrease the 
proinflammatory transcription factor (NFκ B) activity and nuclear 
localization 96 .This suggest a underlying mechanism by which the anti-
inflammatory effects of Acarbose could have been  mediated. This was 
shown by Acarbose which reduces the level of fibrinogen in type 2 
diabetic patients 97 ,and decreases the serum C-reactive protein levels in 
individuals with IGT 98 .Prevoius studies proved that Sitagliptin apart 
from stimulating the AMPK phosporylation it also inhibit the activation 
of MAPK including p38 and ERK 77 – 80 .Sitagliptin could arrest the 
progression of atherosclerosis possibly by AMPK activation and 
suppressing the MAPK, leading to decreases in adhesion molecules and 
inflammatory cytokine. Previous studies showed fall in Plasma 
concentration of C-reactive protein, IL-6 and free fatty acid levels after 
12 weeks of Sitagliptin therapy. It concludes that these effects show a 
promising action of anti-inflammatory effect and thus helps in inhibition 
of atherosclerosis 73. 
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 Figure.11: Synergistic action of Metformin and Sitagliptin 
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Theoretically a synergism occurs in mechanism of action in Sitagliptin 
and Metformin via GLUT4 in reducing the plasma glucose. 
Since both Metformin and Sitagliptin have their effect in reducing the 
blood glucose level and inflammatory markers, this combination will be 
helpful in the reduction of micro and macro vascular complications of 
Type 2 Diabetes Mellitus 
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 Based on this background information , this study  targeted the oral 
hypoglycemic agents like Acarbose and Sitagliptin to look for their anti-
inflammatory action  when it is given as an add on therapy in patients of 
type 2 DM who were already on Metformin Sulfonylurea combination for 
more than one year of treatment and whose HbA1c is >7.5%. 
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MATERIALS AND METHODS 
STUDY DESIGN : 
 A Prospective Open Labelled Comparitive Randomised clinical 
controlled study. 
DATA COLLECTION METHODS: 
 Clinical examination and Lab investigation 
STUDY POPULATION: 
Patients who had attended the Out Patient departments of Endocrinology 
(Dialectology), General Medicine and Master health checkup  unit of 
PSGIMSR Hospitals. 
SAMPLE SIZE: 30 Convenient sample.(Pilot study) 
SAMPLING METHOD:   Simple  Random Sampling. 
INCLUSION CRITERIA: 
• Type 2 Diabetes Mellitus 
• HbA1C >7.5 % 
• Age: 25-65 yrs 
EXCLUSION CRITERIA: 
• Type 1 DM, DM due to genetic defects, GDM 
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• H/o Cardiac, Renal diseases and old CVA. 
• Altered Liver Function Test. 
• H/O Alcohol intake, Smoking. 
• H/o Pancreatitis 
• Patients on Statin group of drugs, Oral Steroid therapy , Fibrate 
therapy. 
DURATION OF STUDY: 3 Months 
METHODOLOGY 
This study was a pilot prospective open labeled randomized controlled 
trial .The study population was Type 2 diabetic patients attending 
Endocrinology and Medicine OPD PSGIMS&R Hospitals Coimbatore. 
We included all type 2 diabetic patients in a age group of around 25-65 
years, who were on conventional treatment of Metformin and 
Sulfonylurea combination drugs and HbA1C level was > 7.5 % .we 
mainly targeted the patients who were still not under control even after 
their usage of conventional treatment. 
Patients with diabetes other than type 2, history of cardiac, renal and 
cerebrovascular diseases, patients on treatment with statins, fibrates and 
steroids, history of altered liver function and pancreatitis, known history 
of alcohol intake and smoking were excluded from the study. 
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The study protocol was approved by the Institute Human Ethics 
Committee (IHEC) preceding the start of the study. The details and the 
purpose of the study protocol were explained to each participant and to 
their attenders individually and clarified their doubts before getting the 
informed consent forms. The informed consents forms provided to the 
participants were either in English or   in Tamil. The participants, who 
gave written informed consent, came under the inclusion criteria were 
enrolled for the study. The copy of consent forms were attached in the 
annexure. The patients who declined to give informed consent were also 
excluded from the study. 
According to the protocol 30 type 2 diabetic patients who fits under our 
inclusion criteria’s were recruited after getting informed consent. Basic 
demographic data’s like name, age and anthropometric measurements of 
Height, weight, body mass index were recorded. History of the patient, 
any co morbidities was noted.  
  Then the clinical examination and the base line investigations  
(Fasting blood glucose, postprandial blood glucose, HbA1C, hsCRP, 
IL6,Plasma Insulin) were done before starting the treatment. Later those 
30 participants were randomly divided into two groups with 15 patients 
per group. One group was on Sitagliptin, Metformin and Sulphonylurea 
combination and the other group was on Acarbose, Metformin and 
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sulphonyl urea combination. Sitagliptin was started on 50mg OD and 
then titrated to 100mg according to the patient’s blood glucose level by 
the physician. In the same way, Acarbose was started on 25mg BD 
initially and later it was titrated to 50mg BD or 25mg TDS according to 
the patient’s blood glucose level .The study participants were followed 
for 3 months and they were advised to come for review after two weeks 
to see whether the dosage of the drugs were enough or they were in need 
for titration of the drug dosage. In between the three months period of 
study, the participant‘s FBS, PPBS levels were noted in the case file. The 
patients were asked to come to receive the drugs (Sitagliptin, Acarbose) 
according to their convenience. Finally at the end of three months study 
participants were asked to come for review and the clinical examination 
and the investigations (FBS, PPBS, HbA1C, IL6, hsCRP and Plasma 
insulin) were done again and the study was completed. Over view of 
study design is given below. 
           
 
 
 
 Figure. 12: Flow Chart representing the Methodology
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This study targets mainly the inflammatory marker and their relationship 
with the clinical, biochemical parameters by checking their level before 
and after the therapeutic management using the following standard 
techniques.  
Plasma glucose 
Patient’s blood samples were collected for fasting and post prandial blood 
sample and sent to biochemistry laboratory.  
Method: 
Enzymatic reference method  with hexokinase. 
Principle: 
Hexokinase (HK) catalyzes the phosphorylation of glucose by ATP 
to form glucose-6 phosphate and ADP. To follow the reaction, a second 
enzyme, glucose-6 phosphate dehydrogenase (G6PDH) is used to 
catalyze oxidation of glucose-6 phosphate by NAD+ to form NADH. 
 
Reaction: 
       HK 
D-glucose + ATP                   D-glucose-6 phosphate +  ADP 
        G6PDH 
D-glucose-6 phosphate + NAD+                          D-6 phosphogluconate  
         +NADH+H+ 
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The concentration of NADH formed is directly proportional to the 
glucose concentration. It is determined by measuring the increase in 
absorbance at 340nm. 
Glycated haemoglobin: (HbA1c) 
Here again the patient’s blood samples were collected in blood collection 
center and sent to biochemistry laboratory for analyzing HbA1C values. 
Method:  
Turbidimetric inhibition immunoassay  
Principle: 
Total Hb and HbA1c concentrations are determined after hemolysis 
of the anti-coagulated whole blood specimen. Total Hb is measured 
colorimetrically. HbA1c is determined immunoturbidimetrically. The 
ratio of both concentrations yields the final percent HbA1c result. 
 
The anti-coagulated whole blood specimen is hemolysed 
automatically with HbA1c hemolysis reagent in the predilution cuvette. 
Erythrocytes are lysed by low osmotic pressure. The released Hb is 
proteolytically degraded to pepsin, to make the beta-N terminal structures 
more accessible for the immunoassay. Additionally, the heme portions 
are oxidized for the Hb assay. 
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Total Hb is dertermined in the hemolysate using a cyanide-free 
colorimetric method based on the formation of a brownish-green 
chromophore (alkaline hematin D-575) in alkaline detergent solution. The 
solor intensity is proportional to the Hb concentration in the sample and is 
determined by monitoring the increase in absorbance at 552nm. The test 
result is calculated using a fixed factor determined from the primary 
calibrator chlorohemin. 
HbA1c is measured using monoclonal antibodies attached to latex 
particles. The antibodies bind the beta-N terminal fragments of HbA1c. 
Remaining free antibodies are agglutinated with a synthetic polymer 
carrying multiple copies of the beta-N terminal structure of HbA1c. The 
change in turbidity is inversely related to the amount of bound 
glycopeptides and is measured turbidimetrically at 552nm. 
 
The final result is expressed as percent HbA1c and is calculated 
from the HbA1c/Hb ratio as follows. 
Protocol 1: According to IFCC 
HbA1c (%) = (HbA1c/Hb)*100 
Protocol 1: According to DCCT/NGSP 
HbA1c (%) = (HbA1c/Hb)*87.6+2.27 
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Plasma insulin 
 Patients blood samples were collected in fasting and and sent to 
biochemistry laboratory for analyzing plasma insulin. 
Method 
It was done in cobas e411 auto analyser  which is based on 
Electrochemiluminescence immunoassay (ECLIA) 
Test principle 
Sandwhich principle. Total duration of assay: 18minutes. 
1st incubation: insulin from 20µl sample, a biotinylated monoclonal 
insulin specific antibody, and a monoclonal insulin-specific antibody 
labeled with a ruthenium complex from a sandwich complex. 
2nd incubation: After addition of streptavidin-coated particles,the complex 
becomes bound to the solid phase via interaction of biotin and 
streptavidin. 
The reaction mixture is aspirated into measuring cell where the 
microparticles are magnetically captured onto the surface of electrode. 
Unbound substances are then removed with procell.Application of a 
voltage to the electrode then induce chemiluminescent emission which is 
measured by a photomultiper. 
Results are determined via a calibration curve which is instrument –
specifically generated by 2-point calibration and a master curve provided 
via the reagent barcode. 
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High Sensitive - CRP 
Sample for High sensitivity C - reactive protein (hs-CRP) was collected 
in red topped vacutainer which is a tube without any anticoagulant. The 
blood samples for Interleukin -6 (IL-6) and Interleukin -18 (IL-18) were 
collected in yellow topped vacutainer which had acid citrate dextrose as 
anticoagulant. 
The high sensitivity CRP was tested in the Clinical Biochemistry lab 
using the Cobas Integra C - reactive protein (Latex). This machine 
utilizes the principle of Particle enhanced turbidimetric assay. Human 
CRP agglutinates with latex particles coated with monoclonal anti-CRP 
antibodies. The precipitate is determined turbidimetrically at 
552nm.Sample collected was centrifuged and the serum was used for 
analyses. The analyzer automatically calculates the analyte concentration 
of each sample. The value <0.05mg/dl was considered to be normal. 
Interleukin-6 
 The Interleukin-6 was estimated in the Pharmacology laboratory 
using Krishgen Biosystems imported from California USA. The IL-6 
enzyme immunoassays are programmed for quantification of human 
interleukin-6(IL-6). Samples and other requirements used for 
quantification are coated in microtiter plate which is previously coated 
with first monoclonal Ab, anti IL-6 in the presence of second antibody 
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linked to streptavidin Horseradish peroxidase (Streptavidin-HRP). After 
when the incubation period is over these wells are washed with the help 
of a colored substrate the enzyme activity is detected. This color is 
proportional to the IL-6 concentration in the serum sample.  
Serum was obtained by allowing the blood to clot for 30 minutes and by 
centrifuging it for 10 mins at 1000 x g. then they were stored. Then the 
serum was separated carefully from clot in a separate plastic tubes and 
stored at < - 20 degree C. 
  The kit contains a plate with ready to use 96 wells. The reagents 
were prepared for assaying IL-6. 5 ml of 20X wash buffer was added to 
95 ml and 1 ml of 5X Assay diluents to 4 ml of distilled water. 25 
microliters of Detection Antibody to 9975µl of 1X Assay Diluents to get 
final volume to 10 ml and 50µl of streptavidin-HRP to 9950µl of 1X 
Assay Diluents to make final volume to 10 ml were added. Recombinant 
protein was diluted by adding 20µl of standard solution in 10 ml of 1X 
Assay Diluents and top standard solution 2000pg/ml was prepared. Six 
two-fold serial dilutions were prepared from the top standard solution 
2000pg/ml such that concentrations are 1000pg/ml, 500pg/ml, 250pg/ml, 
125pg/ml, 62.5pg/ml, 31.3pg/ml and 1X assay diluents serve as zero 
standards . 
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Figure.13: Picture of IL-6 processing in ELISA wells. 
 
100µl/well of standards and samples were added to the plate. After 
sealing it was incubated at 37 degree C for 1 hour and 30 minutes. The 
wells were washed at least for 4 times using the wash buffer 1X and the 
plate was turned upside-down and tapped firmly onto a clean absorbent 
paper.100µl of diluted Detection Antibody was added to each well and 
the plate was sealed and incubated at 37 degree c for 1 hour and 30 
minutes. Again the wells were washed using wash buffer 1X and 100µl of 
diluted streptavidin-HRP was added to each well after which the plate 
was sealed and incubated at 37 degree c for 30 minutes. The wells were 
washed again four times and this time the wells were soaked in wash 
solution for 30 seconds to 60 seconds in between each wash to minimize 
the background error. Finally, freshly prepared TMB substrate 100µl was 
added to each well and incubated in the dark for 15-30 minutes. The wells 
showing positive reaction turned blue in color after which the reaction 
was stopped by adding 100µl of stop solution.  
71 
 
The plate was then inserted into an ELISA reader and the absorbance read 
at 450 nm within 30 minutes of adding stop solution. ELISA reader is a 
Bio-Rad system which is attached to a computer which has curve fitting 
software. The unknown concentrations of interleukin-6 were then 
identified by plotting the graph. 
STATISTICAL ANALYSIS 
Data were analysed using SPSS soft ware version 19.0. Between group 
values were interpreted using independent sample T and paired T test for 
before and after values in both Acarbose and Sitagliptin groups. 
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 Figure. 16: Age distribution among the study participants
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 Figure. 17: Picture of Age distribution in Acarbose and 
Sitagliptin group.
 
This bar diagram shows the age 
and  Sitagliptin gro
yrs of age. Among them 33% belongs to Acarbose group 
patients belongs to Sitagliptin group.
 
1 1
0
1
2
3
4
5
6
7
8
9
10
25-35
 
distribution separately in both Acarbose 
up. In that 47% study participants comes under 45
 
5 5
2
9
35-45 45-55
AGE DISTRIBUTION (n=30)
acarbose sitagliptin
75 
 
- 55 
and 60%  
4
3
55-65
      Figure.18: Family history of Diabetes in Study population
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    Figure.20: History of Hypertension among the Study 
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      Figure.22: Duration of Diabetes in the Study Population
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This diagram shows the duration of diabetes separately in both 
Acarbose and Sitagliptin group.
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 Figure.24: Past treatment pattern in the Study Population
This diagram explains mainly the past treatment pattern of 
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Sitagliptin group.
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    Figure.26: Body mass index of the study population
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  Table.1  Body Mass Index in Acarbose and Sitagliptin 
groups. 
 Acarbose(Mean +SD) Sitagliptin  
(Mean + SD) 
BMI-1 25.20 + 2.84 27.02 +4.64 
BMI-3 25.25 +2.83 26.32 +4.81 
Mean 
difference 
-.056 + 0.79 0.69 +1.04 
p  value 0.796 0.033 
 
Results of Body Mass Index in Acarbose and Sitagliptin groups 
showed no statistical significance even though there is greater reduction 
in Sitagliptin group in which mean value decreased from 27.02 + 4.64 SD 
to 26.32 + 4.81 SD ( p value 0.033) with 95% confidence interval. 
 
 
 
 
 Figure.27: Fasting Blood Sugar status 
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      Table.2: FBS in Acarbose and Sitagliptin groups. 
 Acarbose(Mean +SD) Sitagliptin(Mean + SD) 
FBS-1 183.71 + 44.99 178.07 + 46.73 
FBS-3 142.92 +33.60 138.84 +25.13 
Mean 
difference 
40.78 +47.75 39.23 + 52.50 
p  value 0.007 0.020 
95 % CI 13.21 – 68.35 7.50 -70.95 
 
Results of FBS in this study showed reduction in mean value in 
both Acarbose and Sitagliptin group ranging from 183.71 + 44.99 SD to 
142.92 +33.60 SD,  178.07 + 46.73 SD to  138.84 +25.13 SD  
respectively. This was of statistical significance with p value 0.007, 0.020 
respectively.  There was no significant difference seen in the reduction of 
FBS on comparing Acarbose and Sitagliptin group (p value = 0.725). 
            
  
 Figure.28: Post Prandial Blood Sugar in study population
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Table .3: PPBS   in Acarbose and Sitagliptin groups. 
 Acarbose(Mean +SD) Sitagliptin(Mean + SD) 
PPBS -1 272.35 + 64.08 263.92 + 101.60 
PPBS – 3 204.85 + 57.97 194.23 + 44.50 
Mean difference 67.50 + 76.83 69.69 + 98.3 
p  value 0.006 0.025 
95 % CI 23.13 – 111.86 10.24 -129.14 
 
                 Results of PPBS in this study showed reduction in mean value 
in both Acarbose and Sitagliptin group ranging from 272.35 + 64.08 SD 
to 204.85 + 57.97 SD , 263.92 + 101.60 SD  to 194.23 + 44.50 SD 
respectively. This was of statistical significance with p value 0.006, 0.025 
respectively. But there was no significant difference seen in the reduction 
of PPBS on comparing Acarbose and Sitagliptin group (p value = 0.600). 
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Table.4:  HbA1c status in Acarbose and Sitagliptin groups. 
 
Results of HbA1c in this study showed reduction in mean value in 
both Acarbose and Sitagliptin group ranging from 10.01 + 1.51 SD to 
8.17 + 1.28 SD , 9.69 +1.53 SD to 7.75 + 1.32 SD respectively. This was 
of statistical significance with p value of 0.001, 0.004 respectively. But 
there was no significant difference seen in the reduction of HbA1c on 
comparing the after values of Acarbose and Sitagliptin group (p value 
=0.403). 
     
  
 Acarbose(Mean +SD) Sitagliptin(Mean + SD) 
HbA1c-1 10.01 + 1.51 9.69 + 1.53 
HbA1c – 3 8.17 + 1.28 7.75 + 1.32 
Mean difference 1.83 + 1.67 1.94 + 1.99 
p value 0.001 0.004 
95 % CI 1.018 – 2.80 1.043 – 3.14 
       Figure.30: Plasma Insulin 
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Table. 5: Plasma Insulin status in Acarbose and Sitagliptin 
groups. 
 Acarbose(Mean +SD) Sitagliptin(Mean + SD) 
Insulin -1 18.71 + 16.42 27.72 + 25.98 
Insulin  – 3 14.18 + 6.71 22.58 + 17.68 
Mean difference 4.52 + 16.60 5.13 + 17.9 
p  value 0.327 0.324 
 
Results of Plasma Insulin in this  study showed reduction in mean 
value in both Acarbose and Sitagliptin group ranging from 18.71 + 16.42 
SD to 14.18 + 6.71 SD ,  27.72 +25.98  to  22.58 + 17.68 SD respectively. 
This was of no statistical significance because of  p value = 0.327, 0.324 
respectively. There was also no significant difference seen in the 
reduction of Plasma Insulin on comparing the after values of Acarbose 
and Sitagliptin group (p value =0.110). 
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Table. 6: Insulin Resistance status  in Acarbose and 
Sitagliptin groups. 
 Acarbose(Mean +SD) Sitagliptin(Mean + SD) 
IR-1 9.00 + 8.38 11.49 + 9.42 
IR – 3 5.12 + 3.14 7.63 + 5.78 
Mean 
difference 
3.88 + 8.19 3.86 + 7.84 
p  value 0.100 0.101 
 
Results of IR in this study showed reduction in mean value in both 
Acarbose and Sitagliptin group ranging from 9.00 + 8.38 SD to 5.12 + 
3.14 SD , 11.49 +9.42 SD to 7.63 + 5.78 SD respectively. This was of no 
statistical significance because of  p value = 0.100 , 0.101 respectively. 
There was also no significant difference seen in the reduction of IR on 
comparing the end values of Acarbose and Sitagliptin group (p value 
=0.170). 
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Table. 7: hcCRP  status  in Acarbose and Sitagliptin groups. 
 Acarbose(Mean +SD) Sitagliptin(Mean + SD) 
hs CRP-1 0.58 +0.93 0.45 + 0.43 
hs CRP – 3 0.30+0.3 0.41 + 0.39 
Mean difference 0.27 + 0.89 0.48 + 0.40 
p  value 0.265 0.671 
 
               Results of hsCRP in this study showed reduction in mean value 
in both Acarbose and Sitagliptin group ranging from 0.58 + 0.93 SD to 
0.30 + 0.30 SD, 0.45 + 0.43 SD to 0.41 + 0.39 SD respectively. This was 
of no statistical significance because of  p value = 0.265 , 0.671 
respectively. There was also no significant difference seen in the 
reduction of hsCRP on comparing  the end results Acarbose and  
Sitagliptin group (p value =0.451). 
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  Table.8: IL-6 status in Acarbose and Sitagliptin groups. 
 Acarbose(Mean +SD) Sitagliptin(Mean + SD) 
IL-6(1) 120.01 + 203.3 136.32 + 241.81 
IL-6 (3) 174.08 + 492.1 57.67 + 78.55 
Mean difference -54.07 +36.7 78.64 +269.97 
P value 0.591 0.314 
  
Results of IL-6 in this study showed reduction in mean value of 
Sitagliptin group ranging from 136.32 + 241.81 SD to 57.679 + 78.55 SD 
(p value =0.314 ). But in case of Acarbose group there was little increase 
in IL-6 levels with the mean value ranging from 120.01 + 203.3 SD  to 
174.08 + 492.1 SD .(p value=0.591). There was also no significant 
difference seen in the reduction of hsCRP on comparing the after values 
of Acarbose and Sitagliptin group (p value =0.451). 
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DISCUSSION 
 It is a known one that, the risk of cardiovascular disorder is high in 
both type I and type II Diabetes Mellitus .But, the period of onset is 
different in both types. In case of type I DM risk of CVD arise after some 
decades but in type II DM, it sets very early in the asymptomatic period 
of hyperglycemia and even by the time of diagnosis these patients are at 
potential risk. This is mainly due to the Insulin Resistance, which 
emerges at an early stage of the start of pathogenesis in the type II 
Diabetes Mellitus. Many studies have proven that Insulin resistance was 
the main culprit which cause impairment in insulin signalling pathway 
and there by leading to glucotoxicity, lipogenesis, increase in free fatty 
acid oxidation and inflammation. 
Inflammation which is one of the factors responsible for 
endothelial dysfunction and IR also leads to increase in platelet 
aggregation and all these process collectively lead to atherogenesis and 
cardiovascular disease ultimately. Therapeutic management is the only 
option to intervene these processes, and to prevent or delay the risk of 
macrovascular complications. TNF-α, IL-6, hsCRP are the inflammatory 
markers involved in the process of atherogenesis. Studies have proven 
that the increase in the inflammatory markers would predict the risk of 
cardiovascular complications at the earliest. 
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Few OHA‘s had been proved earlier to reduce the inflammatory 
markers along with hypoglycemic effects thereby being cardio protective. 
This  study was aimed at comparing the inflammatory reduction property 
of Sitagliptin in comparison with Acarbose which was proved to elicit 
anti inflammatory property as an  add –on drug therapy with Metformin 
and Sulfonylurea combination. 
In this study totally 30 type 2 diabetes patients around the age 
group of 25-65 years, on Metformin and Sulfonylurea combination 
,HbA1c value >7.5 were recruited. After getting informed consent and 
randomized into two groups in which one group was added on Acarbose 
and the other group was added with Sitagliptin along with Metformin, 
Sulfonylurea combinations.   
Previous study by Andrew et al, has shown that Obese diabetic 
patients treated with metformin had lower levels of hsCRP ,expression of 
TNF-α and TLR 2/4, than their counterparts receiving placebo 115 .Studies 
have shown that Sulfonylureas didn’t have any cardio protective effect 
because they actually prevent the cardiac preconditioning thereby 
preventing the damage to myocardium84 But still Sulfonylurea effectively 
controls the blood glucose levels and had shown effective outcomes in 
the clinical parameters. Another study  Eberhard Standl et al,  proved that  
Acarbose  could reduce the low grade inflammatory markers like  hsCRP  
and NF-kB activation in type 2 diabetes patients 117,118.  More over 
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Studies done with Sitagliptin have also proven their anti-inflammatory 
effect in type 2 diabetes patients 73. Recently there is an ongoing study on 
Sitagliptin as initial monotherapy for the therapeutic management of type 
2 diabetes mellitus in pediatric participants. When this study proves the 
safety and efficacy of Sitagliptin as initial therapy along with their 
additional beneficial actions of anti-inflammation in pediatric type 2 
diabetes patients, then it will be of great use in preventing or delaying the 
progression of atherogenesis in young patients. 
With this back ground information Sitagliptin and Acarbose were 
given as an  add on therapy with Metformin and Sulfonylurea 
combination. Thus this study aimed to compare the influence of anti-
inflammatory effects of Sitagliptin and Acarbose in patients who were 
already on Metformin Sulfonylurea combination as the mode of 
treatment. 
The study also aimed to compare the before and after values of 
these inflammatory markers in each group separately. Baseline 
inflammatory values were noted during the starting of treatment and those 
30 patients were followed for 3 months and finally the inflammatory 
markers were repeated again at the end of the third month. During the 
study period three patients withdrew from the study due to their poor 
compliance. 
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In this study the results of BMI showed greater reduction in the 
Sitagliptin group with mean value from  27.02 +4.64 SD to 26.32 + 
4.81SD, p value = 0.033 compared to the Acarbose group whose BMI 
value ranges from 25.20 +2.84 SD to  25.25 + 2.83 SD, p=0.796 (Table 
1), (Fig.26). But still there is no much of statistical significance in the 
reduction of BMI values when compared between Acarbose and 
Sitagliptin groups.The study conducted in USA  in the year 2012 by 
Antoine Makdissi et al, has  proven that Sitagliptin  potentially reduces 
the BMI in type 2 Diabetes Mellitus patients . This study results were 
consistent with his study. 
Study conducted by Michael J Theodorakis has shown reduction in 
fasting glucose  levels after Acarbose therapy 116 .and another study 
showed that  in Sitagliptin therapy, the fasting blood glucose was reduced 
after 12 weeks of therapeutic management  73. 
Regarding the results of fasting blood glucose in the Acarbose 
treated group, the  mean value was 183.71 + 44.99 SD  at the starting of 
the study. It was reduced at the end of the three months to the mean value 
of 142.92+ 33.60 SD (Fig.27). The p value was 0.007 which was 
statistically significant with 95% confidence interval. (Table.2) 
In the Sitagliptin group mean value of fasting blood glucose at the 
starting of the study was 178.07+46.73 SD and it was found to be reduced 
at the end of the three months with the mean value of  138.84+25.13 SD 
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(Fig 27). The p value was 0.020 which was statistically significant with 
95% confidence interval.(Table.2) 
Fasting blood glucose at the end of the three months was compared 
between Acarbose and Sitagliptin group. It was found that Acarbose 
group reduces the FBS levels to the mean value of 142.92 +33.60 SD 
compared to the Sitagliptin group which reduced the FBS levels to the 
mean value of 138.84+25.13 SD. Although the mean value was reduced 
greater in Acarbose group but it was not statistically significant because p 
value was found to be 0.725.   
Studies have proven that, there was reduction in the postprandial 
blood glucose when added Acarbose additionally with other oral 
hypoglycemic agents 116. 
In this study results of postprandial blood glucose in the Acarbose 
group, at the starting of the treatment was with the mean value 
272.35+64.08 SD and at the end of the three months the PPBS was 
reduced to the  mean value of 204.85+ 57.97 SD(Fig.28). The p value 
was 0.006 which was statistically significant with 95% confidence 
interval (Table.3). 
In the Sitagliptin group the mean value of postprandial blood 
glucose level at the starting of therapy is 263.92 +101.60 SD  it was 
reduced to the mean value of 194.23+44.50 SD at the end of the three 
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months (Fig 28) . The p value was 0.025 which was statistically 
significant. (Table.3). 
PPBS levels at the end of three months were compared between 
Acarbose and Sitagliptin group. It was found that PPBS levels of 
Sitagliptin group was reduced to the mean value of 194.23+44.50 SD 
compared to the Acarbose group ,whose mean value of PPBS at the end 
of the three months was found to be 204.85+57.97 SD. But finally there 
was no statistical significance in the reduction of PPBS between both the 
groups (Fig 28) 
 Many international studies showed the anti-inflammatory effects of 
Sitagliptin, with  0.7% reduction in the HbA1c value 73 .In the same way 
in this  study in Acarbose and Sitagliptin  treated group the mean value of 
HbA1C at the beginning of  the study period was found to be 10.01+1.51 
SD and 9.69+1.53 SD respectively. The mean value of HbA1c was 
reduced in both the groups at the end of the three months to the mean 
value of 8.17+1.28 SD and 7.75+1.32 SD and p values were 0.001 and 
0.004 respectively with statistical significance (Fig.29) (Table.4). But in 
this study, when compared the mean values of HbA1C  levels at the end 
of the three months in Acarbose and Sitagliptin groups , it was found that 
Sitagliptin group showed greater reduction with the mean value of 
7.75+1.32 SD compared to the Acarbose group whose mean value was 
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found to be 8.17+1.28 SD (Fig.29) . Those results were not statistically 
significant.(p value = 0.403). 
Next parameter which was analysed in this study was regarding the 
plasma insulin levels and the Insulin resistance. At the starting of the 
study, the mean value of Plasma insulin in Acarbose and Sitagliptin group 
were found to be 18.71+16.42 SD and 27.72+25.98 SD 
respectively.(Table.5) (Fig.30). The results of  plasma insulin in Acarbose 
and Sitagliptin groups  at the end of the three months were found to be 
reduced to 14.18+6.71SD and 22.58+17.68 SD with p value=0.327 and 
0.324  respectively. Though the mean values in both the groups were 
reduced, it was not statistically significant. Whereas for Insulin 
Resistance in Acarbose and Sitagliptin group mean value was found to be 
9.00+8.38 SD and 11.49 +9.42 SD  respectively in the starting of 
treatment (Table.6) (Fig.31 ). 
 At the end of the three months in Acarbose and Sitagliptin group 
the mean value of Insulin Resistance were reduced to 5.12+3.14 SD and 
7.63 +5.78 SD respectively (Fig. 31) . Though there was reduction in the 
mean value in both the groups it was not statistically significant.  ( p 
value =0.100 and 0.101 respectively) 
Other studies have proven that Sitagliptin reduces the mean Insulin 
Resistance 73 but not shows greater reduction in the fasting Insulin level. 
Acarbose has proven to reduce the Plasma Insulin level which was done 
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in ealier studies by Michael J Theodorakis et al 28. This study has also  
compared the Plasma Insulin and Insulin Resistance values  at the end of 
the three months between the Acarbose and Sitagliptin group ,the mean 
values were  reduced to 14.18+6.71 SD and 22.58+17.68 SD respectively  
for plasma insulin and 5.12+3.14 SD and 7.63+5.78 SD respectively for 
Insulin resistance (Fig.30,31). But these results were not statistically 
significant. (p value = 0.110  for Plasma Insulin and 0.170 for Insulin 
Resistance. 
 Many studies are in search of the anti-inflammatory effects of 
Acarbose and DPP-4 inhibitors and their potential to reduce the risk of 
cardiovascular diseases. Other studies done on the potential of Acarbose 
to reduce the cardiovascular events which showed the reduction in the 
serum hsCRP levels after the treatment with Acarbose 117,118 .Another 
study formulated by Husam Ghanim et al, which showed the anti-
inflammatory effects of sitagliptin have proven that there was reduction 
in the serum levels of hsCRP and IL-6 after three months treatment of 
Sitagliptin therapy 73 . 
           In this study mean levels of hsCRP at the starting of study in 
Acarbose and Sitagliptin groups were found to be 0.58 +0.93 SD and 0.45 
+ 0.43 SD respectively (Table.7) (Fig.32). At the end of the three months 
levels of hsCRP was reduced in both Acarbose and Sitagliptin group to 
the mean value of 0.30+0.3 SD (p value= 0.265) and 0.41 + 0.39 SD (p 
108 
 
value= 0.671) respectively(Fig 32). Though there is greater reduction in 
mean values of hsCRP levels which were consistent with the results of 
previous studies 117, 118, and 73 these results were not statistically significant 
in this study. 
 When the values of hsCRP were compared between Acarbose and 
Sitagliptin groups,at the end of the three months  there were no statistical 
significance reduction in those hsCRP values (p value=0.451). 
 Next inflammatory marker which this study analysed was the IL-6 
levels. The mean values in the starting of treatment were 120.01 + 203.3 
SD in Acarbose group and 136.32 + 241.81 SD in Sitagliptin group 
(Table.8) (Fig.33). At the end of the three months the mean values of IL-6 
in Sitagliptin group was found to be reduced to 57.69 + 78.55 SD but in 
Acarbose group it was found to be increased to the mean value of 174.08 
+ 492.1 SD. When the before and after values of Sitagliptin group was 
analyzed, it showed reduction in the mean values of IL-6 levels at the end 
of the three months (Fig 33). But there was no statistical significance. 
 When comparing the after values of IL-6 in Acarbose and 
Sitagliptin group, greater reduction was seen in the Sitagliptin group after 
3 months of therapy. Thus the findings in the study was consistent with 
the previous studies which showed the anti- inflammatory of Sitagliptin 
therapy 73 But this is again not statistically significant (p value = 0.408). 
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This study has shown the potential role of Sitagliptin in reducing 
the inflammatory markers apart from reducing the blood glucose level 
when was given as an  add on therapy with Metformin and Sulfonylurea 
combination, as we know the fact that Metformin was already known to 
have anti-inflammatory action. The study which was done in the year 
2011 has proven that initial therapy with Metformin and Sitagliptin 
combination showed superior glycemic improvement and weight loss 
compared with Metformin monotherapy 119 .Hence fixed dose 
combination of Sitagliptin and Metformin may be helpful in preventing or 
delaying the progress of atherogenesis when given at initial therapy in the 
management of type 2 DM. 
Acarbose also reduced the hsCRP levels when given as an add on 
therapy with Metformin which was already known to have anti-
inflammatory action. But there is no such reduction in the IL-6 values, 
Hence further studies with more sample size and a long term follow up of 
minimum of 6-9months period is a must to observe the progression of 
anti-inflammatory action in these groups.  
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CONCLUSION 
In this study Sitagliptin combination  reduced the mean value of 
FBS, PPBS, HbA1c, Plasma Insulin , Insulin Resistance, hsCRP and             
IL-6 , which were similar to the results of previous studies 73,76 ,77,78. 
Regarding the results of the Anti-inflammatory markers in 
Sitagliptin treated group with metformin sulphonylureas combination 
showed a definite reduction in the mean values of both hsCRP, IL-6 
levels after the three months treatment, but still it is not statistically 
significant. This may be due to less sample size (pilot study), the results 
obtained were had wide range of values and the patients were followed 
only for 3 months.  Hence, long term follows up and more sample size 
may be mandatory in future to get the statistically significant reduction in 
the inflammatory markers, but Sitagliptin has a definite role in reducing 
chronic inflammation. Reduction in the mean values of hsCRP and IL-6 
level in Sitagliptin with Metformin Sulfonylurea combination showed the 
anti-inflammatory action since few reference proved the anti-
inflammatory property of Metformin 71,72,115.   This study explained the 
synergism when Sitagliptin given along with Metformin Sulfonylurea 
combination. Based on this study findings fixed dose combination of 
Sitagliptin and Metformin may be helpful in preventing the progress of 
diabetes. 
  In Acarbose combination, there was a reduction in the mean values 
of FBS, PPBS, HbA1c, Plasma Insulin, Insulin Resistance, hsCRP but not 
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IL-6.  When the results of inflammatory markers in Acarbose group were 
analyzed .and compared with previous studies 96, 97, 98, Acarbose also 
reduces the inflammatory markers moderately in this study. This study 
showed a great mean value reduction in hsCRP levels but not in IL-6, 
may be because of small sample size (pilot study), poor compliance of 
patients, and presence of infections during the course of study period, and 
the patients were followed only for 3 months. Hence  long term follow up 
and large sample size may be required to see the progression in the 
reduction of inflammatory markers and the role of these drugs in the 
insulin resistant states.  
This study demonstrated the additive anti inflammatory effect of 
Sitagliptin, as this group of drugs is now in trend and commonly been 
prescribed either as base line therapy or based on the HbA1C values. 
When such anti inflammatory property is pronounced with Sitagliptin, it 
can be sure that addition of Sitagliptin with Metformin will be a 
beneficial combination at the initial therapy to the patients in preventing 
the progression of diabetic related cardio vascular complications 119.In 
future, if there are any clinical studies expressing positive role for 
Sitagliptin as monotheraphy either for prediabetes or Type II diabetic 
state, the patients will have a good benefit in terms of better clinical 
outcome with reduction in the chronic inflammatory status.  
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ABBREVIATIONS 
  
AGE         -        Advanced Glycated End products 
AMPK     -        Adenosine Mono Phosphate 
AP -1      -       Activated protein -1 
ADA       -       American Diabetic Association 
CAD       -       Coronary Artery Disease 
CAMP    -       Cyclic Adenosine Mono Phosphate 
DPP -4    -       Dipeptidyl Peptidase -4 
DM      -   Diabetes Mellitus 
ET -1      -        Endothelin -1 
ERK       -        Extracellular signal Regulated Kinase 
eNOs      -        Endothelin Nitric Oxide Synthatase 
FBS        -        Fasting Blood Sugar 
FFA        -       Free Fatty Acid  
GLUT     -      Glucose Transporter 
GPCR     -      G-Protein Coupled Receptor 
G -6 – P  -       Glucose-6- Phosphate 
G -1 –P   -       Glucose -1- Phosphate 
GLP       -         Glucagon like Peptide 
HbA1c  -        Gylcated Hemoglobin A1C 
HDL      -        High Density Lipoprotein  
hsCRP    -       High Sensitive C- Reactive Protein 
IFG        -        Impaired Fasting Glucose 
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IGT        -        Impaired Glucose Tolerance 
IL -6       -       Interleukin -6 
JNK       -        c- Jun NH 2  Kinase   
MAP     -        Mitogen Activated Protein Kinase 
NFkB    -        Nuclear Factor k B 
NO       -        Nitric Oxide 
OHA     -        Oral Hypoglycemic Agents 
PAI       -        Plasminogen Activator Inhibitor 
PCOS  -        Poly Cystic Ovarian Syndrome 
PGI2     -        Prostacycilin 
PI3 –kinase -   Phosphoinositol -3 Kinase 
PPAR –γ -  - Peroxisomal Proliferative  Activated Receptor  
ROS     -         Reactive Oxygen Species 
SUR     -         Sulfonylurea Receptor 
TLR     -         Toll like Receptor 
TNF –α    -     Tumour Necrosing Factor -α 
VAT      -       Visceral Adipose Tissue 
VLDL    -      Visceral Low Density Lipoprotein 
WAT     -       White Adipose Tissue. 
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